Maximizing the Benefits of Cholesterol-lowering Drugs
Overview
Authors
Affiliations
Purpose Of Review: Drugs to lower LDL-C levels are very widely used. In this brief review, I will use selected recent studies to delineate several important principles that provide a rationale for how to maximize the benefits of using LDL-C lowering drugs to reduce cardiovascular disease. The focus will be on using statins, ezetimibe, and PCSK9 monoclonal antibodies as recent studies have predominantly utilized these agents.
Recent Findings: The key principles to consider when using LDL-C-lowering drugs to reduce cardiovascular disease are: the lower the LDL-C the better; the sooner and the longer one lowers LDL-C the better; the higher the risk of cardiovascular disease the greater the absolute benefit; the higher the baseline LDL-C the greater the absolute benefit; and compared with the benefits of cholesterol-lowering drugs on reducing cardiovascular disease the risk of side effects is very modest.
Summary: Understanding and employing these key concepts in caring for patients will allow one to use cholesterol-lowering drugs wisely to maximize the reduction of cardiovascular events.
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia.
Ahmad M, Hegele R Mol Diagn Ther. 2025; .
PMID: 39875700 DOI: 10.1007/s40291-024-00768-0.
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments.
Abbasi S, Khan A, Choudhry M Cureus. 2024; 16(6):e63078.
PMID: 38919858 PMC: 11196920. DOI: 10.7759/cureus.63078.
Azmi M, Khan F, Asif U, Khurshid B, Wadood A, Qureshi S ACS Omega. 2023; 8(5):5057-5071.
PMID: 36777558 PMC: 9909811. DOI: 10.1021/acsomega.2c07893.
Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.
Pan X Adv Exp Med Biol. 2022; 1372:119-143.
PMID: 35503178 PMC: 11106795. DOI: 10.1007/978-981-19-0394-6_9.
The Role of Lipid Rafts and Membrane Androgen Receptors in Androgen's Neurotoxic Effects.
Fadeyibi O, Rybalchenko N, Mabry S, Nguyen D, Cunningham R J Endocr Soc. 2022; 6(5):bvac030.
PMID: 35308305 PMC: 8926069. DOI: 10.1210/jendso/bvac030.